Airway Inflammation News and Research

RSS

Exercise-induced bronchoconstriction (EIB) guidelines: an interview with Dr Jonathan Parsons, The Ohio State University Asthma Center

Exercise-induced bronchospasm (EIB) is defined as acute, transient airway narrowing that occurs in association with exercise. Exercise-induced bronchospasm can occur during or, more frequently, after exercise.

21 May 2013

Better understanding of cells' development has implications in study of inflammatory diseases

Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.

15 May 2013

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.

8 Mar 2013

Severe childhood asthma blood test hopes dashed

Blood eosinophil counts do not reliably reflect airway eosinophil concentrations in children with severe, therapy-resistant asthma, and therefore cannot be used to make therapeutic decisions, researchers report.

19 Feb 2013

Children in asthma hotspots more likely to experience exercise-induced wheeze

Asthmatic children in New York City neighborhoods with high rates of asthma make many more visits to the emergency room (ER) than those who live in other parts of the city. While socioeconomic factors such as lack of adequate preventive care are part of the equation (high-asthma neighborhoods tend to be lower income), new research points to a possible biological basis for the disparity.

18 Dec 2012

Asthma and nasal congestion common insomnia triggers

Insomnia is a common problem in patients with asthma, suggests research published in Allergy.

30 Nov 2012

Obstructive sleep apnea common in young cystic fibrosis children

Children with stable cystic fibrosis have an increased risk for obstructive sleep apnea, which could cause sleep disruption, researchers report.

2 Nov 2012

House dust protein worsens allergic asthma symptoms

A bacterial protein found in common house dust may worsen a person’s asthmatic response to other indoor allergens, say researchers.

19 Oct 2012

Flagellin in house dust may worsen allergic responses to inhaled substances

A bacterial protein in common house dust may worsen allergic responses to indoor allergens, according to research conducted by the National Institutes of Health and Duke University. The finding is the first to document the presence of the protein flagellin in house dust, bolstering the link between allergic asthma and the environment.

16 Oct 2012

Daily low-dose inhaled corticosteroids do not benefit asthmatics

For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.

12 Sep 2012

Phthalates may be asthma trigger

Research suggests that exposure to two phthalates may be a trigger for asthma-related airway inflammation.

7 Sep 2012

Exposure to phthalates increases risk of asthma-related airway inflammation in children

Children exposed to diethyl phthalate (DEP) and butylbenzyl phthalate (BBzP)-phthalate chemicals commonly found in personal care and plastic products-have elevated risk of asthma-related airway inflammation, according to researchers at Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health.

6 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

28 Aug 2012

OX40 molecule responsible for airway inflammation in the lungs

A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells.

30 Jul 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

Aerocrine’s NIOX MINO and the test kits receive Australian marketing approval

Aerocrine AB announces that its airway inflammation monitor, NIOX MINO, and the NIOX MINO Test Kit, have received marketing approval for the Australian market.

24 May 2012

Airway inflammation linked with asthma-related mortality rates in older adults

Higher mortality rates among older adult asthma patients compared to their younger counterparts may be due, at least in part, to an increase in airway inflammation, according to a study conducted by researchers in Canada, who note that their results imply that elderly patients are either less likely to follow asthma medication dosing instructions, or that the underlying airway inflammation in elderly patients is relatively resistant to current anti-inflammatory therapies.

22 May 2012

Bedfont Scientific Ltd Agree the acquisition of Logan Research Ltd

Bedfont has agreed the acquisition of Logan Research Ltd in a deal to move the company into a new area of scientific applications for breath research.

From Bedfont® Scientific Ltd 25 Apr 2012

ACAAI/AAAAI publish position statement in support of ATS guideline on Aerocrine's FeNO test

Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.

2 Apr 2012